Bone Density in Transgender Youth on Gender-Affirming Hormone Therapy
Journal of the Endocrine Society · 12.03.2024 · 8 (5)
DOI: 10.1210/jendso/bvae045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Endocrine Society, online erschienen am 12.03.2024. Verfasst von Micaela K Roy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO 80045, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIH, NCATS.
Abstract (Originalsprache)
Some transgender youth are treated with gonadotropin-releasing hormone agonists (GnRHa) followed by testosterone or estradiol, which may impact bone mineral density (BMD). This cross-sectional study of transgender youth (n = 56, aged 10.4-19.8 years, 53% assigned female at birth [AFAB]) utilized total body dual-energy x-ray absorptiometry to evaluate BMD Z-scores, and associations between GnRHa duration, body mass index (BMI), and BMD. Participants on GnRHa alone (n = 19, 14 assigned male at birth [AMAB], 5 AFAB) at the time of the study visit were 13.8 [12.8, 15.3] (median [IQR]) years old, had been on GnRHa for 10 [5.5, 19.5] months, and began GnRHa at age 12 [10.4, 12.6] years. Total body BMD Z-score for individuals on GnRHa monotherapy was −0.10 [−0.8, 0.4] (AFAB, female norms) and −0.65 [−1.4, 0.22] (AMAB, male norms). AFAB participants (n = 21) on testosterone were age 16.7 [15.9, 17.8] years, had been on testosterone for 11 [7.3, 14.5] months, and started testosterone at age 16 [14.8, 16.8] years; total body BMD Z-score −0.2 [−0.5, 0] (male norms) and 0.4 [−0.2, 0.7] (female norms). AMAB participants (n = 16) were age 16.2 [15.1, 17.4] years, had been on estradiol for 11 [5.6, 13.7] months, and started estradiol at age 16 [14.4, 16.7] years; total body BMD Z-score −0.4 [−1.1, 0.3] (male norms) and −0.2 [−0.7, 0.6] (female norms). BMD Z-score was negatively correlated with GnRHa duration (male norms: r = −0.5, P = .005; female norms: r = −0.4, P = .029) and positively correlated with BMI (male norms: r = 0.4, P = .003; female norms: r = 0.4, P = .004). In this cross-sectional cohort, total body BMD Z-scores were slightly below average, but lowest in the AMAB group on GnRHa monotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO 80045, USA.
- Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
- Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
- Geriatric Research Education and Clinical Center, Veterans Affairs Eastern Colorado, Aurora, CO 80045, USA.
ORCID-Profile: Samantha Bothwell, Megan M Kelsey, Kerrie L Moreau, Kristen J Nadeau, Micol S Rothman, Natalie J Nokoff
Förderung
- NHLBI NIH HHS
- NIH
- NCATS
- Doris Duke University of Colorado School of Medicine Fund
Zitieren
APA
Roy, M. K., Bothwell, S., Kelsey, M. M., Ma, N. S., Moreau, K. L., Nadeau, K. J., Rothman, M. S., & Nokoff, N. J. (2024). Bone Density in Transgender Youth on Gender-Affirming Hormone Therapy. Journal of the Endocrine Society, 8(5). https://doi.org/10.1210/jendso/bvae045
Vancouver
Roy MK, Bothwell S, Kelsey MM, Ma NS, Moreau KL, Nadeau KJ, et al. Bone Density in Transgender Youth on Gender-Affirming Hormone Therapy. Journal of the Endocrine Society. 2024;8(5). doi:10.1210/jendso/bvae045
BibTeX
@article{Roy2024,
author = {Roy, Micaela K and Bothwell, Samantha and Kelsey, Megan M and Ma, Nina S and Moreau, Kerrie L and Nadeau, Kristen J and Rothman, Micol S and Nokoff, Natalie J},
title = {Bone Density in Transgender Youth on Gender-Affirming Hormone Therapy},
journal = {Journal of the Endocrine Society},
year = {2024},
volume = {8},
number = {5},
doi = {10.1210/jendso/bvae045}
}
EUVIMED